Loading data for EYPT — first visit, this takes a few seconds.
EyePoint, Inc. (EYPT)
NasdaqGM: EYPT
· Real-Time Price · USD
4.41
-0.09 (-2.00%)
At close: Sep 01, 2026, 3:59 PM
The price, the headline numbers and the latest news, in one place.
EyePoint, Inc. (EYPT) Stock Price, Analysis & Data
-2.00% (1D)
| Bid | 9 |
| Market Cap | 384M |
| Revenue (ttm) | 2.79M |
| Net Income (ttm) | -307M |
| 1.74 | |
| -3.75 | |
| n/a | |
| -1.66 | |
| P/B (ttm) | 11.57 |
| P/S (ttm) | 141.63 |
| Earnings Date | Nov 4, 2026 |
| Ask | 24 |
| Volume | 200,445 |
| Avg. Volume (20D) | 3,167,158 |
| Open | 4.40 |
| Previous Close | 4.50 |
| Day's Range | 4.38 - 4.55 |
| 52-Week Range | 3.95 - 19.11 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About EYPT
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and pat...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 27, 2005
Employees 214
Stock Exchange NasdaqGM
Ticker Symbol EYPT
Website https://eyepoint.bio
Financial Performance
In 2025, EyePoint's revenue was 31.37M, a decrease of -27.5% compared to the previous year's 43.27M. Earnings were -231.96M, an increase of 77.25%.
Financial StatementsEarnings Surprise
EyePoint has released their quarterly earnings on Aug 5, 2026:
- Revenue of $507K misses estimates by $0, with -90.49% YoY decline.
- EPS of -1.09 misses estimates by -0.13, with -28.24% YoY decline.
EyePoint, Inc. is scheduled to release its earnings on Nov 4, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2